94 results
8-K
EX-99.1
LYEL
Lyell Immunopharma, Inc.
7 Aug 24
Lyell Immunopharma Reports Business Highlights and Financial Results for the Second Quarter 2024
4:06pm
-GAAP(1)
(1)There was no income tax effect related to the adjustments made to calculate non-GAAP net loss because of the full valuation allowance … on our net U.S. deferred tax assets for all periods presented.
Lyell Immunopharma, Inc.
Unaudited Reconciliation of GAAP to Non-GAAP Research
424B5
LYEL
Lyell Immunopharma, Inc.
6 May 24
Prospectus supplement for primary offering
8:12am
and Drug Administration’s (FDA) Orphan Drug designation (ODD), including potential tax credits for qualified clinical trials, prescription drug user-fee … , sale or other assignment, if any;
a discussion of any material or special United States federal income tax considerations applicable to the preferred
8-K
EX-99.1
LYEL
Lyell Immunopharma, Inc.
6 May 24
Lyell Immunopharma Reports Business Highlights and Financial Results for the First Quarter 2024
8:03am
- Non-GAAP(1)
(1)There was no income tax effect related to the adjustments made to calculate non-GAAP net loss because of the full valuation allowance … on our net U.S. deferred tax assets for all periods presented.
Lyell Immunopharma, Inc.
Unaudited Reconciliation of GAAP to Non-GAAP Research
S-3
EX-1.2
mybd1
28 Feb 24
Shelf registration
7:49pm
S-3
EX-4.5
j5svmm iy60i
28 Feb 24
Shelf registration
7:49pm
S-3
5rk948mfm0z rl
28 Feb 24
Shelf registration
7:49pm
S-3
EX-4.9
luc4o77
28 Feb 24
Shelf registration
7:49pm
S-3
EX-4.7
pw5gmcvpry3o
28 Feb 24
Shelf registration
7:49pm
S-3
EX-4.8
wu5ob2hsjfmkc9a0
28 Feb 24
Shelf registration
7:49pm
8-K
EX-99.1
h6041nd0m1
28 Feb 24
Lyell Immunopharma Reports Business Highlights and Financial Results for the Fourth Quarter and Full Year 2023
4:07pm
8-K
EX-99.1
uwoeuxuibsmr9u0
7 Nov 23
Lyell Immunopharma Reports Business Highlights and Financial Results for the Third Quarter 2023
4:08pm